Aptahem AB — Investor Relations & Filings

Aptahem AB is a clinical-stage biotechnology company focused on developing aptamer-based pharmaceuticals for acute, life-threatening conditions. The company's technology utilizes aptamers, which are synthetic RNA-based molecules that can serve as an alternative to antibodies. Its lead candidate, Apta-1, is in clinical development for the treatment of sepsis and other critical inflammatory conditions involving a combination of coagulation, inflammation, and tissue damage. Apta-1 is designed with a multi-mechanistic profile to address the complex pathophysiology of these diseases, targeting a significant unmet medical need for which there are currently no effective specific treatments.